Essential medicines lists are meant to promote equity in health by ensuring that quality medicines are available and accessible in a functioning health system, in appropriate forms, at affordable prices, and distributed in an equitable fashion ([@B1]). The World Health Organization (WHO) Model List of Essential Medicines ("WHO Model List") ([@B2]) is revised biannually ([@B3]). The WHO Model List serves as a guide for countries' national essential medicines lists (NEMLs), which prioritize a core set of medicines based on each country's health needs ([@B1], [@B4]). NEMLs are used to guide medicine selection, appropriate use, medicine reimbursement, and medicine procurement, and they should be regularly updated ([@B5], [@B6]).

NEMLs guide medicine access for over 600 million people in the Region of the Americas ([@B7]). All countries with an NEML in the Americas are Member States of the Pan American Health Organization (PAHO), which works with countries to improve and protect the health of the people in their nation or territory ([@B8]).

In total, PAHO consists of 49 countries and territories (35 Member States plus 14 others categorized as participating, associate, or observer states) ([@B9]). PAHO promotes evidence-based choices for the countries' NEML medicine selection through its Regional Revolving Fund for Strategic Public Health Supplies (the "Strategic Fund") ([@B10]). The Strategic Fund has created its own list of medicines, based on the WHO Model List ([@B11]), that are available for procurement on behalf of PAHO Member States to leverage economies of scale in order to assist countries in the acquisition of quality, safe and effective medicines and other health supplies and services at affordable prices ([@B12]). The Strategic Fund also aims to build capacity at the national level for drug supply management and procurement programming and planning ([@B12]).

To our knowledge, no studies have compared NEMLs across countries in the Americas. This study sought to compare available NEMLs in the Americas with the WHO Model List (20^th^ edition, 2017) to determine potential recommendations for NEMLs in the Americas.

METHODS
=======

Creation of the database
------------------------

In June of 2017 we searched the WHO Essential Medicines and Health Products Information Portal, an online repository that contains hundreds of publications on medicines and health products related to WHO priorities ([@B13], [@B14]). We included all NEMLs that were posted on that repository, irrespective of their publication date and language. When more than one NEML was found for a country, the most recent was used. Detailed explanation of these methods is described elsewhere ([@B15]). The original database was updated with an NEML from Panama, and with other minor corrections.

Exclusion criteria
------------------

We excluded documents that were not NEMLs, such as prescribing guidelines, and some medicines, including diagnostic agents, antiseptics, disinfectants, and saline solutions.

Data extraction
---------------

From each country's NEML, medicines were abstracted using International Nonproprietary Names ([@B16]). For medicines whose names were not in English we used the Anatomical Therapeutic Chemical (ATC) classification system, if available, or translated the names with the help of the Google Translate website ([@B17], [@B18]). Each medicine was listed individually, whether it was part of a combination product or not. Medicine bases and their salts were combined (e.g., promethazine hydrochloride and promethazine), as well as different compounds of the same vitamin or mineral (e.g., ferrous fumarate and ferrous sulfate). Detailed methods for the creation of the database, including data extraction, are described elsewhere ([@B15]).

Data analysis
-------------

We determined the number of differences between each country's NEML and the WHO Model List (20^th^ edition, 2017), including both the number of medicines on the WHO Model List but not on the respective NEML and the number of medicines on the respective NEML but not on the WHO Model List. Also for the countries in the Americas we determined the number of medicines that were on each NEML and on the PAHO Strategic Fund list, and the number of medicines that were not on each NEML but were on the Strategic Fund list.

Similarity scores were calculated for the 31 countries in the Americas by dividing medicines into two groups, those that were commonly listed (≥ 50%) and those that were uncommonly listed (\< 50%). For each country's NEML, a similarity score was calculated by totaling commonly listed medicines and uncommonly listed medicines, and then subtracting uncommonly listed from commonly listed medicines. Higher numbers indicate more similarity and lower scores indicate less similarity, in comparison to other NEMLs in the Americas.

Withdrawn medicines on NEMLs were identified in a previous study ([@B19]). We determined which ones were present on NEMLs in the Americas and calculated the number present on each country's NEML.

RESULTS
=======

We included NEMLs from 138 countries: 31 in the Americas (89% of the 35 PAHO Member States) and 107 outside of the Americas ([@B15]). PAHO Member States that did not have an NEML in the online WHO NEMLs repository were the Bahamas, Canada, Guatemala, and the United States of America. The publication years for the NEMLs in the Americas ranged from 2004 to 2017.

The number of medicines on the individual lists from the Americas lists ranged from 197 to 704 (median: 361; interquartile range (IQR): 290 to 456) ([Table 1](#tbl01){ref-type="table"}). In comparison, the values for other world regions were: Africa, 64 to 702 (median: 298; IQR: 248 to 347); Eastern Mediterranean, 200 to 964 (median: 462; IQR: 278 to 623); Europe, 181 to 980 (median: 398; IQR: 285 to 601); Southeast Asia, 44 to 546 (median: 291; IQR: 230 to 343); and Western Pacific, 177 to 742 (median: 249; IQR: 215 to 295) ([@B15]).

In total, the 138 NEMLs contained 2 081 unique medicines. We identified 1 264 medicines included on the lists of the Americas, of which more than two-fifths (541; 43%) were listed by 3 or fewer countries.

Comparison with the WHO Model List
----------------------------------

We determined the number of differences between each country's NEML and the WHO Model List, including both the number of medicines on the WHO Model List but not on the NEML and the number of medicines on the NEML but not on the WHO Model List ([@B15]). At the time of our study, the WHO Model List had 415 medicines on it. The number of differences between NEMLs in the Americas and the WHO Model List ranged from 175 to 531 (median: 295; IQR: 265 to 347) ([Table 1](#tbl01){ref-type="table"}). The values for the other world regions were: Africa, 208 to 538 (median: 281; IQR: 267 to 323); Eastern Mediterranean, 93 to 753 (median: 352; IQR: 249 to 502); Europe, 211 to 813 (median: 415; IQR: 337 to 535); Southeast Asia, 231 to 463 (median: 273; IQR: 243 to 329); and Western Pacific, 239 to 595 (median: 307; IQR: 284 to 347) ([@B15]).

###### National essential medicines lists in the Region of the Americas

  Country                              ISO-3[^a^](#TFNa){ref-type="fn"} Country code   Health expenditure per capita (\$Intl; 2015)[^b^](#TFNb){ref-type="fn"}   NEML Year   Total number of medicines on NEML   Total differences from WHO Model List   No. of medicines on WHO Model List, but not on NEML   No. of medicines on NEML, but not on WHO Model List   No. of medicines on Strategic Fund list   No. of medicines on Strategic Fund list but not on NEML   Similarity score among countries
  ------------------------------------ ----------------------------------------------- ------------------------------------------------------------------------- ----------- ----------------------------------- --------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------- --------------------------------------------------------- ----------------------------------
  Antigua and Barbuda                  ATG                                             1 105                                                                     2007        292                                 291                                     207                                                   84                                                    90                                        90                                                        204
  Argentina                            ARG                                             1 390                                                                     2011        469                                 312                                     129                                                   183                                                   126                                       54                                                        113
  Barbados                             BRB                                             1 234                                                                     2011        624                                 507                                     149                                                   358                                                   118                                       62                                                        −60
  Belize                               BLZ                                             524                                                                       2008        370                                 279                                     162                                                   117                                                   110                                       70                                                        134
  Bolivia (Plurinational State of)     BOL                                             446                                                                       2011        353                                 270                                     166                                                   104                                                   124                                       56                                                        169
  Brazil                               BRA                                             1 392                                                                     2014        406                                 347                                     178                                                   169                                                   117                                       63                                                        12
  Chile                                CHL                                             1 903                                                                     2005        349                                 314                                     190                                                   124                                                   110                                       70                                                        153
  Colombia                             COL                                             853                                                                       2011        371                                 288                                     166                                                   122                                                   120                                       60                                                        125
  Costa Rica                           CRI                                             1 287                                                                     2014        389                                 354                                     190                                                   164                                                   108                                       72                                                        85
  Cuba                                 CUB                                             2 479                                                                     2012        505                                 358                                     134                                                   224                                                   133                                       47                                                        45
  Dominica                             DMA                                             586                                                                       2007        284                                 295                                     213                                                   82                                                    89                                        91                                                        202
  Dominican Republic                   DOM                                             873                                                                       2015        356                                 175                                     117                                                   58                                                    136                                       44                                                        172
  Ecuador                              ECU                                             980                                                                       2013        370                                 243                                     144                                                   99                                                    133                                       47                                                        118
  El Salvador                          SLV                                             579                                                                       2009        361                                 268                                     161                                                   107                                                   116                                       64                                                        157
  Grenada                              GRD                                             678                                                                       2007        282                                 303                                     218                                                   85                                                    85                                        95                                                        196
  Guyana                               GUY                                             336                                                                       2010        280                                 265                                     200                                                   65                                                    96                                        84                                                        156
  Haiti                                HTI                                             120                                                                       2012        197                                 248                                     233                                                   15                                                    88                                        92                                                        155
  Honduras                             HND                                             353                                                                       2009        366                                 325                                     187                                                   138                                                   106                                       74                                                        112
  Jamaica                              JAM                                             511                                                                       2012        456                                 343                                     151                                                   192                                                   122                                       58                                                        104
  Mexico                               MEX                                             1 009                                                                     2011        704                                 531                                     121                                                   410                                                   133                                       47                                                        −162
  Nicaragua                            NIC                                             406                                                                       2011        272                                 261                                     202                                                   59                                                    106                                       74                                                        180
  Panama                               PAN                                             1 543                                                                     2017        601                                 398                                     106                                                   292                                                   143                                       37                                                        −65
  Paraguay                             PRY                                             724                                                                       2009        307                                 272                                     190                                                   82                                                    114                                       66                                                        161
  Peru                                 PER                                             671                                                                       2012        424                                 243                                     117                                                   126                                                   140                                       40                                                        138
  Saint Kitts and Nevis                KNA                                             1 443                                                                     2007        290                                 297                                     211                                                   86                                                    89                                        91                                                        206
  Saint Lucia                          LCA                                             681                                                                       2007        290                                 297                                     211                                                   86                                                    89                                        91                                                        206
  Saint Vincent and the Grenadines     VCT                                             470                                                                       2010        267                                 250                                     199                                                   51                                                    100                                       80                                                        201
  Suriname                             SUR                                             1 017                                                                     2014        285                                 260                                     195                                                   65                                                    103                                       77                                                        151
  Trinidad and Tobago                  TTO                                             2 204                                                                     2010        492                                 377                                     150                                                   227                                                   122                                       58                                                        58
  Uruguay                              URY                                             1 748                                                                     2011        518                                 445                                     171                                                   274                                                   109                                       71                                                        −14
  Venezuela (Bolivarian Republic of)   VEN                                             579                                                                       2004        306                                 289                                     199                                                   90                                                    116                                       64                                                        160

***Table 1 notes:*** ISO-3: International Organization for Standardization alpha-3 letter codes; \$Intl: International dollars; NEML: national essential medicines list; Strategic Fund List (refers to the Pan American Health Organization - Regional Revolving Fund for Strategic Public Health Supplies); WHO: World Health Organization.

***Source:*** Authors' results and data from publicly available sources as summarized below:

We obtained the countries' alpha three-letter codes from the International Organization for Standardization (ISO) 3166-1, Online Browsing Platform.

Health care expenditure per capital from the WHO/Global Health Observatory data repository.

In the Americas, 23 medicines from the WHO Model List were not included on any NEML ([Table 2](#tbl02){ref-type="table"}) ([@B15]). The Dominican Republic, Mexico, and Peru included more than 290 (70%) of the medicines on the WHO Model List on their NEMLs. Of these NEMLs, the Dominican Republic and Peru listed medicines from the WHO Model List without adding many other medicines (fewer than 130), while Mexico added over 400 medicines to its list that were not on the WHO Model List. Dominica, Grenada, Haiti, Saint Kitts and Nevis, and Saint Lucia omitted over 207 (50%) of the medicines on the WHO Model List from their NEMLs ([Table 1](#tbl01){ref-type="table"}).

For neglected tropical diseases, there were two medicines (benznidazole and nifurtimox) for American trypanosomiasis (Chagas disease) and five antileishmaniasis medicines (amphotericin B, miltefosine, paromomycin, meglumine, and stibogluconate) on the WHO Model List. Ten countries in the Americas listed at least one medicine to treat Chagas disease, while 30 countries listed at least one medicine to treat leishmaniasis. Haiti was the only country that did not list any treatment for either disease.

Countries in the Americas with lower health care expenditures appear to have omitted more WHO essential medicines from their lists (e.g., Haiti and Nicaragua), and countries with higher health care expenditures appear to have included more medicines on their lists that are not on the WHO Model List (e.g., Barbados, Mexico, Panama, and Uruguay), although there are exceptions (e.g., Antigua and Barbuda) ([Figure 1](#fig01){ref-type="fig"}).

Comparison with the Strategic Fund list
---------------------------------------

The Strategic Fund list includes 180 unique medicines; 95% of listed medicines are also included on the WHO Model List. The number of medicines listed on both the Strategic Fund list included on any national essential medicines list in the Region and a specific country's NEML ranged from 85 to 143 (median: of the Americas 114; IQR: 100 to 124) ([Table 1](#tbl01){ref-type="table"}). Six countries (Cuba, Dominican Republic, Ecuador, Mexico, Panama, and Peru) included more than 126 (70%) of the Strategic Fund medicines on their respective NEML.

###### Medicines listed by the WHO Model List but not included on any national essential medicines list in the Region of the Americas

  Medicines (ATC code)                               Strategic Fund listed
  -------------------------------------------------- -----------------------
  Artenimol/Dihydroartemisinin (P01BE05)             Yes
  Bedaquiline (J04AK05)                              Yes
  Delamanid (J04AK06)                                Yes
  Dolutegravir (J05AX12)                             Yes
  Mifepristone (G03XB01)                             Yes
  Piperaquine (P01BX02)                              Yes
  Protionamide/Prothionamide (J04AD01)               Yes
  Rifapentine (J04AB05)                              Yes
  Velpatasvir (J05AP55)                              Yes
  Ceftaroline (J01DI02)                              No
  Cyclizine (R06AE03)                                No
  Daptomycin (J01XX09)                               No
  Eflornithine (P01CX03)                             No
  Etonogestrel-releasing implant (G03AC08)           No
  Faropenem (J01DI03)                                No
  Japanese encephalitis vaccine (J07BA02)            No
  Melarsoprol (P01CD01)                              No
  Progesterone vaginal ring (G03DA04)                No
  Protease (A09AA02)                                 No
  Pyronaridine (P01BF06)                             No
  Suramin (P01CX02)                                  No
  Tick-borne encephalitis immunoglobulin (J06BB12)   No
  Ulipristal (G03AD02)                               No

ATC: Anatomical Therapeutic Chemical classification system. WHO Model List refers to the World Health Organization's Model List of Essential Medicines, 20th version (2017); Strategic Fund listed indicates that the medicines are included on the Pan American Health Organization (PAHO) Strategic Fund Medicine List (September 2018).

***Source:*** Authors' results.

The number of medicines listed on the Strategic Fund list and not on a specific country's NEML ranged from 37 to 95 (median: 66; IQR: 56 to 80) ([Table 1](#tbl01){ref-type="table"}). We identified 9 medicines that are listed on both the Strategic Fund list and the WHO Model List but not by any country in the Americas ([Table 2](#tbl02){ref-type="table"}); these medicines are commonly used in the treatment of hepatitis C, tuberculosis, human immunodeficiency virus, and malaria. Atovaquone (ATC: P01AX06), which is used in the treatment of malaria, pneumocystis pneumonia, and toxoplasmosis, is not on the WHO Model List or any NEML in the Americas but is included on the Strategic Fund list.

Velpatasvir, a medicine used in combination for treatment of hepatitis C, was not listed by any NEML in the Americas. Seven other medicines for hepatitis C (daclatasvir, dasabuvir, ledipasvir, ombitasvir, paritaprevir, sofosbuvir, and simeprevir) were each listed by fewer than three countries. All of these medicines for hepatitis C treatment are included on the Strategic Fund list. The other medicines included on the WHO Model List for the treatment of hepatitis C are ribavirin and pegylated interferon alfa, which are used in combination; only six countries in the Americas (Brazil, Cuba, Honduras, Mexico, Panama, and Uruguay) listed these medicines.

![Health expenditure and dissimilarities between national essential medicines lists of the Americas and WHO Model List](rpsp-44-e5_Figure1){#fig01}

WHO: World Health Organization (Model List of Essential Medicines, 20th edition, 2017).

The width of the circles represents the country's health expenditure. We obtained the countries' three-letter codes from the International Organization for Standardization (ISO) 3166-1 Online Browsing Platform; ATG: Antigua and Barbuda; ARG: Argentina; BRB: Barbados; BLZ: Belize; BOL: Bolivia (Plurinational State of); BRA: Brazil; CHL: Chile; COL: Colombia; CRI: Costa Rica; CUB: Cuba; DMA: Dominica; DOM: Dominican Republic; ECU: Ecuador; SLV: El Salvador; GRD: Grenada; GUY: Guyana; HTI: Haiti; HND: Honduras; JAM: Jamaica; MEX: Mexico; NIC: Nicaragua; PAN: Panama; PER: Peru; PRY: Paraguay; KNA: Saint Kitts and Nevis; LCA: Saint Lucia; VCT: Saint Vincent and the Grenadines; SUR: Suriname; TTO: Trinidad and Tobago; URY: Uruguay; VEN: Venezuela (Bolivarian Republic of).

***Source:*** Authors' results.

Four antituberculosis medicines rifapentine (treatment of protionamide (part of treatment regimens for multidrug and extensively drug-resistant tuberculosis)) are not listed on any NEML in the Americas. These medicines are included on the WHO Model List and the Strategic Fund list.

Between-country comparisons
---------------------------

The similarity scores for the Americas, measuring the extent to which countries tend to list medicines commonly listed by other countries in the Americas, ranged from −162 to 206 (median: 151; IQR: 85 to 172) ([Table 1](#tbl01){ref-type="table"}). Most countries in the Americas had a positive similarity score, indicating that most of the medicines listed by those countries were also listed by the majority of countries included in this analysis. Mexico had a large negative similarity score (−162), indicating that the majority of medicines on its list were not listed by most countries in the Americas.

Discrepant medicines
--------------------

We identified medicines that could be added or removed from NEMLs in the Americas by calculating whether medicines were commonly listed (listed by ≥ 50% of countries) in each WHO region. Medicines that are not commonly listed in the Americas but are on the WHO Model List and commonly listed by at least three other regions (50% of the WHO regions) could be considered for addition ([Table 3](#tbl03){ref-type="table"}). Medicines commonly listed within the Americas but not on the WHO Model List or not commonly listed by any other region could be considered for removal ([Table 3](#tbl03){ref-type="table"}).

Withdrawn medicines are those that have been withdrawn after market approval or those that were not approved by a national regulatory body because of adverse effects ([@B19]). Withdrawn medicines were present on all the NEMLs of the Americas; these ranged from 2 to 24 medicines (median: 8; IQR: 4 to 12) ([Table 4](#tbl04){ref-type="table"}). Of the 31 studied countries in the Americas, 10 of them (32%) listed 11 or more withdrawn medicines. Three internationally withdrawn medications were present on NEMLs in the Americas: drotrecogin alfa (Mexico); nikethamide (Cuba); and thioridazine, an antipsychotic that was withdrawn by the manufacturer (Novartis) in 2005 ([@B19]), (listed by 18 of the 31 countries in the Americas (58%)).

DISCUSSION
==========

We found that NEML listings across countries in the Americas are similar to each other, with a few exceptions (including Barbados, Mexico, Panama, and Uruguay), and similar to the WHO Model List ([Table 1](#tbl01){ref-type="table"}). Some medicines listed by multiple countries in the Americas could be considered for removal because they are not listed in either the WHO Model List or by many other countries (e.g., trifluoperazine) or because they have been withdrawn in other countries (e.g., thioridazine). Some medicines that are not listed by many countries in the Americas should be considered for addition, such as medicines on the Strategic Fund list (e.g., tuberculosis treatments).

The WHO states that medicine availability and price are key indicators of access to treatment ([@B20]). NEMLs are commonly used to guide public sector procurement ([@B20]), and they have been shown to be more available than other medicines, particularly in the public sector ([@B21]). Therefore, the content of an NEML can affect health outcomes.

###### Medicines that may be considered for addition or removal from national essential medicines lists in the Region of the Americas, with the medicines' Anatomical Therapeutic Chemical classification system code

  Possible action/Medicines
  ------------------------------------------
  Potential additions
   Calamine (D04AX)
   Cefixime (J01DD08)
   Clomifene/Clomiphene (G03GB02)
   Clomipramine (N06AA04)
   Copper IUD (G02BA02)
   Cycloserine (J04AB01)
   Ephedrine (C01CA26)
   Niclosamide (P02DA01)
   Ofloxacin (J01MA01)
   Rabies vaccine (J07BG)
   Tetracaine (C05AD02)
   Vecuronium (M03AC03)
  Potential removals
   Amino acids (B05BA01)
   Dimenhydramine/Dimenhydrinate (R06AA52)
   Diphenhydramine (R06AA02)
   Glutaraldehyde (D08AX09)
   Indinavir (J05AE02)
   Labetalol (C07AG01)
   Metamizole/Dipyrone (N02BB02)
   Methylphenidate (N06BA04)
   Mitomycin (L01DC03)
   Nelfinavir (J05AE04)
   Proxymetacaine/Proparacaine (S01HA04)
   Sevoflurane (N01AB08)
   Thalidomide (L04AX02)
   Thioridazine (N05AC02)
   Trifluoperazine (N05AB06)

***Source:*** Authors' results.

The WHO recommends that their Model List be used to guide countries to the best evidence-based medicines and not necessarily be replicated on NEMLs. Countries should select medicines based on their own, specific priority health care needs ([@B20]). Having a larger overlap of medicines with the WHO Model List may not guarantee better health outcomes for countries. Health care services and quality of care are also important factors that may affect health outcomes. The purpose of a comparison with the WHO Model List is to encourage countries to evaluate their list based on our findings to ensure that their NEMLs use the best evidence-based medicines to meet the needs of their country. We acknowledge that there are other factors, such as relationships with pharmaceutical manufacturers and structural differences within health systems, that may influence NEML listing decisions.

List comparisons
----------------

Within the Americas, Mexico's NEML was the least like those of other countries, as it was the longest (at 704 medicines) and it had the lowest similarity score. Countries may find that with a longer NEML it is harder to maintain an adequate and consistent supply of medicines, therefore the WHO recommends that countries list a limited number of carefully selected medicines ([@B20]). The reasons for Mexico's longer list are not clear; Mexico is not the wealthiest country in the Americas, nor does it have the largest population ([@B7]). Policy process or political factors, such as limited use of evidence-based processes in selecting medicines, as has been demonstrated in other settings, may explain observed differences among NEMLs ([@B22]).

###### Withdrawn medicines included on national essential medicines lists in the Region of the Americas

  Withdrawn medicine (ATC code)                            Safety concern                                          Countries listing the medicine (no.)
  -------------------------------------------------------- ------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Benzbromarone (M04AB03)                                  Hepatic damage                                          Panama (1)
  Benzbromarone (M04AB03)                                  Hepatic damage                                          Panama (1)
  Bismuth (A02BX05)                                        Encephalopathy                                          Argentina, Belize, Cuba, Jamaica, Mexico, Panama, Peru, Suriname, Trinidad and Tobago, Uruguay (10)
  Carisoprodol (M03BA02)                                   Abuse potential                                         Guyana (1)
  Chloral hydrate (N05CC01)                                Tumorigenicity                                          Barbados, Belize, Chile, Costa Rica, Cuba, Ecuador, Honduras, Jamaica, Mexico, Panama (10)
  Chlormadinone (G03DB06)                                  Tumorigenicity                                          Mexico (1)
  Chloroform (N01AB02)                                     Cardiotoxicity, tumorigenicity                          Trinidad and Tobago (1)
  Cisapride (A03FA02)                                      Cardiac arrhythmias                                     Barbados, Mexico, Uruguay (3)
  Clioquinol (D08AH30)                                     Subacute myelo-optic neuropathy (SMON), neurotoxicity   Barbados, Mexico, Panama, Trinidad and Tobago (4)
  Clobutinol (R05DB03)                                     Long QT syndrome, cardiac arrhythmias                   Chile (1)
  Clofibrate (C10AB01)                                     Death, ventricular arrhythmias                          Barbados, Uruguay (2)
  Diclofenac (M01AB05)                                     Gastrointestinal, skin reactions                        Antigua and Barbuda, Argentina, Barbados, Belize, Bolivia, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela (Bolivarian Republic of) (30)
  Dienestrol (G03CB01)                                     Carcinogenicity                                         Costa Rica (1)
  Diethylstilbestrol/Stilboestrol (G03CB02)                Tumorigenicity                                          Argentina, Belize, Costa Rica, Cuba, Guyana, Jamaica, Panama, Peru (8)
  Droperidol/Dehydrobenoperidol (N05AD08)                  Cardiotoxicity                                          Argentina, Bolivia, Chile, Costa Rica, Cuba, Jamaica, Nicaragua (7)
  Drotrecogin alfa (B01AD10)[^\*^](#TFN3){ref-type="fn"}   Failure to show benefits                                Mexico (1)
  Etretinate (D05BB01)                                     Teratogenicity                                          Trinidad and Tobago (1)
  Fluvoxamine (N06AB08)                                    Teratogenicity, nephrotoxicity                          Barbados, Panama, Trinidad and Tobago (3)
  Furazolidone (G01AX06)                                   Carcinogenic, skin                                      Argentina, Colombia, Nicaragua, Peru (4)
  Gatifloxacin (J01MA16)                                   Dysglycemia                                             Barbados (1)
  Gemfibrozil (C10AB04)                                    Adverse effects not balanced by benefits                Argentina, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, Nicaragua, Paraguay, Peru, Venezuela (Bolivarian Republic of) (13)
  Kaolin (A07BC02)                                         No evidence it works for its purpose                    Trinidad and Tobago (1)
  Ketorolac (M01AB15)                                      Gastrointestinal, skin reactions                        Barbados, Bolivia, Dominican Republic, Ecuador, El Salvador, Honduras, Mexico, Nicaragua, Paraguay, Trinidad and Tobago (10)
  Lindane/Gamma benzene hexachloride                       Potential toxicity (P03AB02)                            Barbados, Belize, Guyana, Jamaica, Uruguay, Venezuela (Bolivarian Republic of) (6)
  Meclizine (R06AE05)                                      Teratogenic potential                                   Cuba (1)
  Megestrol (G03AC05)                                      Tumorigenicity                                          Argentina, Barbados, Honduras, Mexico, Panama, Uruguay (6)
  Meprobamate (N05BC01)                                    Abuse                                                   Cuba (1)
  Metamizole/Dipyrone (N02BB02)                            Agranulocytosis                                         Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Guyana, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay, Venezuela (Bolivarian Republic of) (17)
  Metaproterenol/Orciprenaline (R03AB03)                   Cardiotoxicity                                          Mexico (1)
  Methylphenidate (N06BA04)                                Abuse                                                   Antigua and Barbuda, Argentina, Barbados, Belize, Bolivia, Chile, Colombia, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Honduras, Jamaica, Mexico, Panama, Peru, Saint Kitts and Nevis, Saint Lucia, Suriname, Trinidad and Tobago, Uruguay, Venezuela (Bolivarian Republic of) (23)
  Minocycline (A01AB23)                                    Dizziness, vertigo                                      Argentina, Barbados, Brazil, Cuba, Mexico (5)
  Neomycin (A01AB08)                                       Abuse                                                   Antigua and Barbuda, Argentina, Barbados, Belize, Bolivia, Chile, Colombia, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guyana, Jamaica, Mexico, Saint Kitts and Nevis, Saint Lucia, Suriname, Trinidad and Tobago, Uruguay (20)
  Nikethamide (R07AB02)[^\*^](#TFN3){ref-type="fn"}        Neurotoxicity                                           Cuba (1)
  Nimesulide (M01AX17)                                     Hepatotoxicity                                          Venezuela (Bolivarian Republic of) (1)
  Phenazopyridine (G04BX06)                                Carcinogenicity                                         Barbados, Costa Rica, El Salvador, Jamaica, Mexico, Uruguay (6)
  Phentolamine (C04AB01)                                   Carcinogenicity                                         Argentina, Colombia, Cuba, Trinidad and Tobago, Venezuela (Bolivarian Republic of) (5)
  Phenylpropanolamine (R01BA01)                            Hemorrhagic stroke                                      Mexico (1)
  Phthalylsulfathiazole (A07AB02)                          Granulocytopenia                                        Uruguay (1)
  Pioglitazone (A10BG03)                                   Risk of bladder cancer                                  Barbados, Jamaica, Mexico, Uruguay (4)
  Pseudoephedrine (R01BA02)                                Neurotoxicity, gastrointestinal                         Barbados, El Salvador, Jamaica (3)
  Rimonabant (A08AX01)                                     Psychiatric                                             Mexico (1)
  Rosiglitazone (A10BG02)                                  Cardiotoxicity                                          Barbados, Honduras, Mexico, Paraguay, Trinidad and Tobago (5)
  Sulfacetamide (S01AB04)                                  Eye, skin reactions                                     Colombia, Cuba, Haiti, Jamaica, Mexico, Nicaragua, Peru (7)
  Sulfathiazole (J01EB07)                                  Nephrotoxicity, hepatotoxicity, skin reactions          Cuba (1)
  Tegaserod maleate (A06AX06)                              Increased risk of heart attacks and strokes             Mexico (1)
  Thalidomide (L04AX02)                                    Teratogenicity                                          Argentina, Barbados, Bolivia, Brazil, Colombia, Costa Rica, Cuba, Ecuador, El Salvador, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname, Uruguay (17)
  Thioridazine (N05AC02)[^\*^](#TFN3){ref-type="fn"}       Cardiac arrhythmias, QT prolongation                    Antigua and Barbuda, Barbados, Belize, Bolivia, Chile, Colombia, Cuba, Dominica, Grenada, Guyana, Nicaragua, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Uruguay, Venezuela (Bolivarian Republic of) (18)
  Tolcapone (N04BX01)                                      Hepatotoxicity                                          Brazil (1)
  Tranylcypromine (N06AF04)                                Drug-drug interactions                                  Argentina (1)
  Trazodone (N06AX05)                                      Carcinogenicity                                         Colombia (1)
  Triazolam (N05CD05)                                      Psychiatric adverse effects                             Mexico (1)
  Valdecoxib (M01AH03)                                     Cardiotoxicity, skin reactions                          Panama (1)
  Vigabatrin (N03AG04)                                     Neurotoxicity                                           Brazil, Costa Rica, Cuba, Mexico (4)
  Zopiclone (N05CF01)                                      Carcinogenicity                                         Barbados (1)

ATC: Anatomical Therapeutic Chemical classification system.

Medicine has been withdrawn worldwide.

***Source:*** Data retrieved from Charles et al. ([@B19]); data available from the corresponding author of this study.

There is fair overlap between medicines on the NEMLs and those with a negotiated price through the Strategic Fund list. This suggests that the Strategic Fund list may be influential in its intended goal of helping countries to improve access to some medicines. At the same time, some high-priced medicines on the Strategic Fund list are not on most of the NEMLs, including treatments for hepatitis C, human immunodeficiency virus, tuberculosis, and malaria. This suggests that further work may be needed to make these medicines affordable, and perhaps price concerns have held up their listings on NEMLs.

We found that hepatitis C medicine listings on NEMLs are lacking in the Americas, with only 5 of 31 countries in the Americas (16%) having at least one treatment for it. That is despite the fact that the Strategic Fund list includes medicines for treating hepatitis C. Due to medical advances, 95% of people infected with hepatitis C could be cured. However, across the Americas, the vast majority of infected people do not have affordable access to these highly effective medicines ([@B23]).

Mifepristone, which is used in emergency contraception and in therapeutic abortions, is included on the Strategic Fund list and on the WHO Model List (since 2006) with the note "where permitted under national law and where culturally acceptable"; it is not included by any country in the Americas.

Antituberculosis medicines like protionamide have been listed on the WHO Model List for decades. In addition, in April 2015, rifapentine (for latent tuberculosis infections) and bedaquiline and delamanid (latest second-line treatment for multidrug-resistant infection) were added to the WHO Model List ([@B24]); as such, only NEMLs published after 2015 may have included these medicines.

The Dominican Republic and Panama were the only countries in the Americas that had an NEML published in 2015 or later, as of the time that we captured our study data. Ultimately, the choice of medicines included on NEMLs resides with national policymakers, and it is the responsibility of countries to regularly update and publish their NEMLs.

Along with the medications identified for addition, when comparing NEMLs to the WHO Model List and the Strategic Fund list, other medicines were identified that countries could consider adding to their NEMLs ([Table 3](#tbl03){ref-type="table"}). If many regions outside of the Americas are commonly listing particular medicines (e.g., cefixime and ephedrine), there is a consensus that they are essential among those countries. Therefore, medicines that were commonly listed on NEMLs in other regions could be considered for addition to NEMLs in the Americas, keeping in mind each country's epidemiological needs.

NEML medicine removals
----------------------

We assessed medicines that countries could consider removing from their NEMLs ([Table 3](#tbl03){ref-type="table"}). If many countries outside of the Americas are not commonly listing particular medicines (e.g., labetalol), there may be a consensus among those countries that they are not essential. Several medicines on NEMLs in the Americas were identified as not approved or as withdrawn from the market due to adverse effects of the medicine (e.g., chloral hydrate and thioridazine) ([Table 4](#tbl04){ref-type="table"}). NEMLs are meant to guide medicine prescribing ([@B5], [@B1]), and it is important that they be reviewed regularly and that medicines with questionable evidence be carefully considered for omission from the lists. In this way, known harms to the population that a list serves can be prevented.

Treatments for priority noncommunicable disease interventions identified in three WHO guidelines---Best Buys ([@B25]), PEN ([@B26]), and HEARTs technical package ([@B5])---were present in most countries in the Americas, according to previous studies. Areas identified for improvement were influenza vaccination, human papillomavirus vaccine, and senna (sennosides) ([@B27]).

Strengths and limitations
-------------------------

This is the first and largest study comparing the medicines included in 31 NEMLs in the Region of the Americas. The size of the study offers some robustness to the findings, particularly our suggestions for NEML revisions in the Americas.

Our study has limitations. The database of NEMLs and medicines may not reflect current NEML listings, given that documents available from the WHO's NEML repository were abstracted in 2017. In addition, some NEMLs required translation, standardized medicine nomenclature was not consistently used on some lists, and judgments had to be made about what to include in ambiguous cases. These issues made the process liable to errors. This quantitative analysis does not account for other contextual factors that could explain differences in which medicines are included on each NEML, such as local disease prevalence or national priorities.

Conclusions
-----------

Countries in the Americas have NEMLs that are similar and that have significant overlap with both the WHO and Strategic Fund lists. However, countries in the Americas were lacking NEML coverage of medicines for treatment of hepatitis C, human immunodeficiency virus, tuberculosis, and malaria. Regularly updating NEMLs (as recommended by the WHO) and purchasing medicines through the Strategic Fund may help improve access to essential medicines and universal health coverage in the Americas. This may lead to improvements in measurable health outcomes and ultimately better the health of people in the Americas.

Recommendations
---------------

When updating their NEMLs, studied countries in the Americas should consider the differences between their respective NEML and the WHO Model List and the other NEMLs in the Americas. Countries should also assess adding or removing medications from their NEML based on listings in other WHO regions, and they should also weigh removing medications that were withdrawn, particularly ones that have been withdrawn worldwide.
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